紫杉醇联合顺铂方案对局部晚期宫颈癌患者MACC1及Ezrin蛋白表达的影响

Influence of paclitaxel combined with cisplatin on the expressions MACC1 and Ezrin protein in the treatment of locally advanced cervical cancer

目的:探讨紫杉醇联合顺铂方案对局部晚期宫颈癌患者MACC1及Ezrin蛋白表达的影响。方法:选取2013年8月至2015年8月收入本院的68例局部晚期宫颈癌患者为研究对象,采用随机数字表法分为观察组和对照组,各34例。对照组接受顺铂联合5-氟尿嘧啶辅助化疗,观察组采用紫杉醇联合顺铂辅助化疗。持续治疗6周后,分析比较两组患者的临床治疗效果、MACC1和Ezrin蛋白表达情况。结果:观察组的客观缓解率显著高于对照组(χ~2=10.16,P<0.05),观察组的MACC1和Ezrin蛋白表达显著低于对照组(P<0.05),不良反应发生率(11.8%)与对照组(17.6%)差异无统计学意义(χ~2=0.40,P>0.05)。结论:紫杉醇联合顺铂用于局部晚期宫颈癌辅助化疗效果显著,能够有效降低宫颈癌组织中的MACC1与Ezrin蛋白的表达,有利于患者康复,值得临床推广。

Objective： To explore the influence of paelitaxel combined with cisplatin on the expressions MACC1 and Ezrin protein in the treatment of locally advanced cervical cancer. Methods： Sixty eight cervical cancer patients from August 2013 to August 2015 in our hospital were selected as the research objects, who were divided into observation group （34 cases）, and control group （34 cases）. The control group received the therapy of cisplatin plus 5-fluorouracil adjuvant chemotherapy. The observation group received the neoadjuvant chemotherapy of paclitaxel combined with cisplatin. The treatment efficacy and MACC1 and Ezrin protein expressions were compared between the two groups and analyzed after 6 weeks. Results： The clinical efficiency in the observation group were significantly higher than that of control group by chi- square test for comparison, the difference was significant （P 〈 0.05 ）. Compared with the control group, the observation group showed lower expressions of the MACC1 and Ezrin protein, there was a significant difference （ P 〈 0.05 ）. There was no difference of the ADR between the groups （x^2 = 0.40,P 〉 0.05 ）. Conclusion ： The implementation of paclitaxel combined with eisplatin in the treatment of locally advanced cervical cancer was significantly effective, it can significantly reduce the expressions of MACCland Ezrin protein, achieve ideal surgical effect, which is worthy of promotion.